We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04900337
Recruitment Status : Recruiting
First Posted : May 25, 2021
Last Update Posted : May 25, 2021
Sponsor:
Information provided by (Responsible Party):
Amorphical Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo and BAT for the treatment of Moderate to Severe COVID-19 patients. The purpose of this study is to assess the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC).

Condition or disease Intervention/treatment Phase
Covid19 Drug: AMOR 18 Powder & Inhalation Drug: Placebo Phase 1 Phase 2

Detailed Description:

This study includes two parts:

Part 1 - A training period of a single arm active treatment open label, to assess the optimal method of study drug administration, as well as the safety of the combined administration, on 5 patients.

Following DSMB review of the data collected in part 1 and the DSMB approval to proceed to next part, part 2 will be initiated.

Part 2 - A randomized (1:1) placebo controlled 2 arms study. Additional 95 patients will be recruited to this arm.

Patients who are hospitalized due to moderate or severe COVID-19 will be recruited to this study.

The following elements are the main elements that will be assessed:

  1. Confirmation SARS-CoV-2 infection
  2. Respiratory Function (breathing rate, SpO2 Oxygen Saturation
  3. Vital Signs (BP, HR), Temperature
  4. Blood Tests
  5. Disease Severity Scale (8 points ordinal scale)

The whole study period per patient will be 22 days (21 treatment days) or until the patient has recovered and/or is discharged from the hospital, whichever comes first.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Prospective Randomized Placebo Controlled Study to Assess the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Administered Sublingual and in Inhalation Concomitantly With BAT (Best Available Care) as Compared to Placebo and BAT for the Treatment of Moderate to Severe COVID-19 Patients.
Actual Study Start Date : February 9, 2021
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: AMOR 18 Powder & Inhalation

AMOR_inhaled Double Pack- Each kit contains two tubes that after mixing result with 1.14 % ACC in 10 ml suspension.

AMOR_powder- ACC in a dry powder (up to 2000mg Calcium/day sublingually).

 Drug: AMOR 18 Powder & Inhalation
AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
Placebo Comparator: Placebo

Placebo_Inhaled Double Pack - Each kit contains two tubes of saline at different volumes (similar to investigational product) after mixing the results remains saline at a final volume of 10ml.

Placebo_Powder: Each sachet contains powder at the same particle size and weight as the powder of the investigational product.

 Drug: Placebo
Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change of Severity rating of Disease using an 8-point ordinal scale on days 7, 14, 21, measured as improvement greater than or equal to 1 point from baseline score. [ Time Frame: Treatment Day 1 to Day 21 or discharge from hospital, the earliest. ]

    Ordinal 8 points scale:

    1. Not hospitalized and no limitations of activities.
    2. Not hospitalized, with limitation of activities, home oxygen requirement, or both.
    3. Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control or other nonmedical reasons).
    4. Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (related to Covid-19 or to other medical conditions).
    5. Hospitalized, requiring any supplemental oxygen.
    6. Hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices.
    7. Hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
    8. Death.


Secondary Outcome Measures :
  1. Duration of Hospital stay [ Time Frame: Date of hospitalization to treatment day 21 or discharge, whichever comes first. ]
    Time to discharge from hospital

  2. Duration of ICU stay [ Time Frame: Treatment Day 1 to treatment day 21 or discharge, whichever comes first. ]
    Time patient is hospitalized in ICU, if applicable.

  3. Duration of Mechanical Ventilation Use [ Time Frame: Treatment Day 1 to treatment day 21 or discharge, whichever comes first. ]
    Time the patient requires Mechanical Ventilation (if needed)

  4. Duration of Oxygen Supplementation [ Time Frame: Treatment Day 1 to treatment day 21 or discharge, whichever comes first. ]
    Time the patient requires Oxygen Supplementation (if needed)

  5. Duration of No Oxygen use [ Time Frame: Treatment Day 1 to treatment day 21 or discharge, whichever comes first. ]
    Time the patient does not require Oxygen Supplementation

  6. % of patients to meet ordinal scale of 3 or less [ Time Frame: Treatment Day 1 to treatment day 21 or discharge, whichever comes first. ]
    Proportion of subjects hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control or other nonmedical reasons).

  7. % of death [ Time Frame: Treatment Day 1 to treatment day 21 or discharge, whichever comes first. ]
    Proportion of subjects died during the study, if any.

  8. Frequency and severity of adverse events [ Time Frame: Screening to End of treatment day 21 or discharge, whichever comes first. ]
  9. Number and percent of patients with hypercalcemia [ Time Frame: Treatment days 4, 7, 11, 17 and 21. ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females of age ≥ 18 years and ≤ 80 years
  2. Signed an Informed Consent
  3. Agree to undergo blood tests as per protocol
  4. Diagnosed with COVID-19
  5. Evidence of lung involvement (by chest X rays or lung US)
  6. May or may not need for Supplemental Oxygen at enrollment
  7. Hospitalized

Exclusion Criteria:

  1. Pregnant or breast-feeding females
  2. Patients with non-COVID19 related Pneumonia
  3. Any pulmonary disease not related to COVID19
  4. Tracheostomy
  5. High flow oxygen or non-invasive ventilation (Bipap) or Mechanical ventilation
  6. Hypercalcemia defined as calcium or corrected calcium > 10.5mg/dL
  7. Hyperphosphatemia defined as > 4.5mg/dL
  8. Urine calcium to creatinine ratio >0.14
  9. Participating in another clinical study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04900337


Contacts
Layout table for location contacts
Contact: Yehudit Natan 08-6115024 dity@amorphical.com

Locations
Layout table for location information
Israel
Shamir MC Recruiting
Be'er Ya'aqov, Israel
Contact: Ronit Zaidenstein, Dr.    08-9779999    ronitz@shamir.gov.il   
Tel-Aviv Sourasky MC Recruiting
Tel Aviv, Israel
Contact: David Zeltser, Prof.    03-6974093    Davidz@tlvmc.gov.il   
Ziv MC Recruiting
Tsefat, Israel
Contact: Kamal Abu-Jabal, Dr.    077-3631261    kamala@ziv.gov.il   
Sponsors and Collaborators
Amorphical Ltd.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Amorphical Ltd.
ClinicalTrials.gov Identifier: NCT04900337    
Other Study ID Numbers: AMCS-COVID-001
First Posted: May 25, 2021    Key Record Dates
Last Update Posted: May 25, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases